AU2018201767B2 - Controlled release and taste masking oral pharmaceutical composition - Google Patents
Controlled release and taste masking oral pharmaceutical composition Download PDFInfo
- Publication number
- AU2018201767B2 AU2018201767B2 AU2018201767A AU2018201767A AU2018201767B2 AU 2018201767 B2 AU2018201767 B2 AU 2018201767B2 AU 2018201767 A AU2018201767 A AU 2018201767A AU 2018201767 A AU2018201767 A AU 2018201767A AU 2018201767 B2 AU2018201767 B2 AU 2018201767B2
- Authority
- AU
- Australia
- Prior art keywords
- pharmaceutical composition
- oral pharmaceutical
- human
- budesonide
- administration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000008203 oral pharmaceutical composition Substances 0.000 title claims description 90
- 238000013270 controlled release Methods 0.000 title abstract description 17
- 230000000873 masking effect Effects 0.000 title abstract description 8
- VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 claims description 179
- 229960004436 budesonide Drugs 0.000 claims description 164
- 229920001577 copolymer Polymers 0.000 claims description 18
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims description 12
- 235000010445 lecithin Nutrition 0.000 claims description 12
- 239000000787 lecithin Substances 0.000 claims description 12
- 229940067606 lecithin Drugs 0.000 claims description 12
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims description 11
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 claims description 10
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 10
- 235000021355 Stearic acid Nutrition 0.000 claims description 7
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims description 7
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims description 7
- 239000008117 stearic acid Substances 0.000 claims description 7
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 5
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims description 5
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 5
- 235000019359 magnesium stearate Nutrition 0.000 claims description 5
- 239000002700 tablet coating Substances 0.000 claims 3
- 238000009492 tablet coating Methods 0.000 claims 3
- 239000011159 matrix material Substances 0.000 abstract description 158
- 239000000203 mixture Substances 0.000 abstract description 139
- 239000004480 active ingredient Substances 0.000 abstract description 41
- 238000004090 dissolution Methods 0.000 abstract description 17
- 210000001035 gastrointestinal tract Anatomy 0.000 abstract description 6
- 239000013060 biological fluid Substances 0.000 abstract description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 85
- 238000000034 method Methods 0.000 description 67
- 239000003826 tablet Substances 0.000 description 40
- 235000014113 dietary fatty acids Nutrition 0.000 description 32
- 239000000194 fatty acid Substances 0.000 description 32
- 229930195729 fatty acid Natural products 0.000 description 32
- 238000009472 formulation Methods 0.000 description 30
- 150000004665 fatty acids Chemical class 0.000 description 25
- 229920000642 polymer Polymers 0.000 description 24
- 150000001875 compounds Chemical class 0.000 description 20
- 239000008187 granular material Substances 0.000 description 20
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 18
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 18
- 150000002148 esters Chemical class 0.000 description 18
- 230000002178 gastroprotective effect Effects 0.000 description 17
- 239000011253 protective coating Substances 0.000 description 17
- 239000002904 solvent Substances 0.000 description 17
- 239000002775 capsule Substances 0.000 description 16
- 239000000546 pharmaceutical excipient Substances 0.000 description 16
- 238000000576 coating method Methods 0.000 description 14
- 239000011248 coating agent Substances 0.000 description 13
- 238000013265 extended release Methods 0.000 description 13
- 150000005846 sugar alcohols Polymers 0.000 description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 13
- 239000003814 drug Substances 0.000 description 12
- 229940002671 entocort Drugs 0.000 description 12
- 208000002551 irritable bowel syndrome Diseases 0.000 description 12
- 229920003145 methacrylic acid copolymer Polymers 0.000 description 12
- CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 description 11
- -1 glycol alkyl ethers Chemical class 0.000 description 11
- 230000003111 delayed effect Effects 0.000 description 10
- 150000002634 lipophilic molecules Chemical class 0.000 description 10
- 238000002844 melting Methods 0.000 description 10
- 230000008018 melting Effects 0.000 description 10
- 229920002126 Acrylic acid copolymer Polymers 0.000 description 9
- 229920002678 cellulose Chemical class 0.000 description 9
- 235000010980 cellulose Nutrition 0.000 description 9
- 229940079593 drug Drugs 0.000 description 9
- 239000000975 dye Substances 0.000 description 9
- 230000035515 penetration Effects 0.000 description 9
- 238000010521 absorption reaction Methods 0.000 description 8
- 239000001913 cellulose Chemical class 0.000 description 8
- 229940106189 ceramide Drugs 0.000 description 8
- 150000001783 ceramides Chemical class 0.000 description 8
- 238000002156 mixing Methods 0.000 description 8
- 239000004014 plasticizer Substances 0.000 description 8
- 229920001353 Dextrin Chemical class 0.000 description 7
- 239000004375 Dextrin Chemical class 0.000 description 7
- 150000001298 alcohols Chemical class 0.000 description 7
- 239000000783 alginic acid Substances 0.000 description 7
- 235000010443 alginic acid Nutrition 0.000 description 7
- 229920000615 alginic acid Polymers 0.000 description 7
- 229960001126 alginic acid Drugs 0.000 description 7
- 150000004781 alginic acids Chemical class 0.000 description 7
- 239000008366 buffered solution Substances 0.000 description 7
- 150000001841 cholesterols Chemical class 0.000 description 7
- 235000019425 dextrin Nutrition 0.000 description 7
- 238000007922 dissolution test Methods 0.000 description 7
- 239000012530 fluid Substances 0.000 description 7
- 150000002632 lipids Chemical class 0.000 description 7
- 239000003960 organic solvent Substances 0.000 description 7
- 230000002035 prolonged effect Effects 0.000 description 7
- 150000003839 salts Chemical class 0.000 description 7
- 150000003626 triacylglycerols Chemical class 0.000 description 7
- 239000001993 wax Substances 0.000 description 7
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 6
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 6
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 description 6
- 239000004698 Polyethylene Substances 0.000 description 6
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 6
- 229920002472 Starch Polymers 0.000 description 6
- 150000001408 amides Chemical class 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- 125000004432 carbon atom Chemical group C* 0.000 description 6
- LYCAIKOWRPUZTN-UHFFFAOYSA-N ethylene glycol Natural products OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 6
- 229920013821 hydroxy alkyl cellulose Polymers 0.000 description 6
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 229920001277 pectin Polymers 0.000 description 6
- 239000001814 pectin Substances 0.000 description 6
- 235000010987 pectin Nutrition 0.000 description 6
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 6
- 150000008104 phosphatidylethanolamines Chemical class 0.000 description 6
- 229920001223 polyethylene glycol Polymers 0.000 description 6
- 229920001282 polysaccharide Polymers 0.000 description 6
- 239000005017 polysaccharide Substances 0.000 description 6
- 150000004804 polysaccharides Chemical class 0.000 description 6
- 239000000600 sorbitol Substances 0.000 description 6
- 235000019698 starch Nutrition 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 206010009900 Colitis ulcerative Diseases 0.000 description 5
- 208000011231 Crohn disease Diseases 0.000 description 5
- 201000006704 Ulcerative Colitis Diseases 0.000 description 5
- 210000001072 colon Anatomy 0.000 description 5
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical class OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 5
- 230000002496 gastric effect Effects 0.000 description 5
- 229920001477 hydrophilic polymer Polymers 0.000 description 5
- 230000036470 plasma concentration Effects 0.000 description 5
- 238000005070 sampling Methods 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 239000007916 tablet composition Substances 0.000 description 5
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 4
- 239000006185 dispersion Substances 0.000 description 4
- 235000020937 fasting conditions Nutrition 0.000 description 4
- 239000000017 hydrogel Substances 0.000 description 4
- 238000004898 kneading Methods 0.000 description 4
- 239000008108 microcrystalline cellulose Substances 0.000 description 4
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 4
- 229940016286 microcrystalline cellulose Drugs 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 229920003134 Eudragit® polymer Polymers 0.000 description 3
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 3
- 238000007906 compression Methods 0.000 description 3
- 230000006835 compression Effects 0.000 description 3
- XXJWXESWEXIICW-UHFFFAOYSA-N diethylene glycol monoethyl ether Chemical compound CCOCCOCCO XXJWXESWEXIICW-UHFFFAOYSA-N 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 230000029142 excretion Effects 0.000 description 3
- 150000002433 hydrophilic molecules Chemical class 0.000 description 3
- 210000002429 large intestine Anatomy 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 239000002207 metabolite Substances 0.000 description 3
- 239000008188 pellet Substances 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 230000009885 systemic effect Effects 0.000 description 3
- 239000010936 titanium Substances 0.000 description 3
- 230000036325 urinary excretion Effects 0.000 description 3
- 210000002700 urine Anatomy 0.000 description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 229920003139 Eudragit® L 100 Polymers 0.000 description 2
- 229920003141 Eudragit® S 100 Polymers 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- DOOTYTYQINUNNV-UHFFFAOYSA-N Triethyl citrate Chemical compound CCOC(=O)CC(O)(C(=O)OCC)CC(=O)OCC DOOTYTYQINUNNV-UHFFFAOYSA-N 0.000 description 2
- 239000003125 aqueous solvent Substances 0.000 description 2
- 210000001815 ascending colon Anatomy 0.000 description 2
- 230000001174 ascending effect Effects 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 239000004203 carnauba wax Substances 0.000 description 2
- 235000013869 carnauba wax Nutrition 0.000 description 2
- 230000001055 chewing effect Effects 0.000 description 2
- 239000008119 colloidal silica Substances 0.000 description 2
- 229940075557 diethylene glycol monoethyl ether Drugs 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000007970 homogeneous dispersion Substances 0.000 description 2
- 239000008240 homogeneous mixture Substances 0.000 description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 2
- 210000003405 ileum Anatomy 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 229960001375 lactose Drugs 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 125000005395 methacrylic acid group Chemical group 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 239000008185 minitablet Substances 0.000 description 2
- 238000007873 sieving Methods 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 235000012239 silicon dioxide Nutrition 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 239000001069 triethyl citrate Substances 0.000 description 2
- 235000013769 triethyl citrate Nutrition 0.000 description 2
- VMYFZRTXGLUXMZ-UHFFFAOYSA-N triethyl citrate Natural products CCOC(=O)C(O)(C(=O)OCC)C(=O)OCC VMYFZRTXGLUXMZ-UHFFFAOYSA-N 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 description 1
- SBASXUCJHJRPEV-UHFFFAOYSA-N 2-(2-methoxyethoxy)ethanol Chemical compound COCCOCCO SBASXUCJHJRPEV-UHFFFAOYSA-N 0.000 description 1
- WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 description 1
- 241000252983 Caecum Species 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 239000004150 EU approved colour Substances 0.000 description 1
- 229920003136 Eudragit® L polymer Polymers 0.000 description 1
- 229920003137 Eudragit® S polymer Polymers 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 239000000227 bioadhesive Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000004181 carboxyalkyl group Chemical group 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 210000004534 cecum Anatomy 0.000 description 1
- 230000000112 colonic effect Effects 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 210000001731 descending colon Anatomy 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 239000012738 dissolution medium Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 238000002565 electrocardiography Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000001125 extrusion Methods 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000000622 irritating effect Effects 0.000 description 1
- 229960001021 lactose monohydrate Drugs 0.000 description 1
- 229920003113 low viscosity grade hydroxypropyl cellulose Polymers 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 229960001855 mannitol Drugs 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 238000003801 milling Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 235000021313 oleic acid Nutrition 0.000 description 1
- 150000002889 oleic acids Chemical class 0.000 description 1
- 229940006093 opthalmologic coloring agent diagnostic Drugs 0.000 description 1
- 239000005022 packaging material Substances 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-N palmitic acid group Chemical group C(CCCCCCCCCCCCCCC)(=O)O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 229920000193 polymethacrylate Polymers 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- FKTOIHSPIPYAPE-UHFFFAOYSA-N samarium(III) oxide Inorganic materials [O-2].[O-2].[O-2].[Sm+3].[Sm+3] FKTOIHSPIPYAPE-UHFFFAOYSA-N 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 235000003441 saturated fatty acids Nutrition 0.000 description 1
- 150000004671 saturated fatty acids Chemical class 0.000 description 1
- 210000001599 sigmoid colon Anatomy 0.000 description 1
- 229960001866 silicon dioxide Drugs 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 229940083466 soybean lecithin Drugs 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 210000003384 transverse colon Anatomy 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Abstract Controlled release and taste masking compositions containing one or more active principles inglobated in a three-component matrix structure, i.e. a structure formed by successive amphiphilic, lipophilic or inert matrices and finally inglobated or dispersed 5 in hydrophilic matrices. The use of a plurality of systems for the control of the dissolution of the active ingredient modulates the dissolution rate of the active ingredient in aqueous and/or biological fluids, thereby controlling the release kinetics in the gastrointestinal tract. 10051682_1 (GHMatters) P88749.AU.2 13/03/18
Description
CONTROLLED RELEASE AND TASTE MASKING ORAL PHARMACEUTICAL COMPOSITION
This application is a divisional application of Australian Patent Application No. 2016203566, the disclosure of which is incorporated herein by reference. Most of the disclosure of that application is also included herein, however, reference may be made to the specification of Australian Patent Application No. 2016203566 as filed to gain further understanding of the invention claimed herein. The specifications for Australian Patent Application No. 2016203566 and its parent, Australian Patent Application No. 2011248587, are entirely incorporated herein by reference.
The present invention relates to controlled release, delayed release, prolonged release, extended release and/or taste masking compositions containing budesonide as active ingredient incorporated in a three-component matrix structure, i.e. a structure formed by successive amphiphilic, lipophilic or inert matrices and finally incorporated or dispersed 15 in hydrophilic matrices. The use of a plurality of systems mechanism for the control of the dissolution of the active ingredient modulates the dissolution rate of the active ingredient in aqueous and/or biological fluids, thereby controlling the release kinetics in the gastrointestinal tract, and it also allows the oral administration of active principles having unfavourable taste characteristics or irritating action on the mucosae of the
0 administration site, particularly in the buccal or gastric area.
The compositions of the invention are suitable to the oral administration or the efficaciously deliver the active ingredient acting topically at some areas of the gastrointestinal tract.
TECHNOLOGICAL BACKGROUND
The preparation of a sustained, controlled, delayed, extended or anyhow modified release form can be carried out according to different techniques:
1. The use of inert matrices, in which the main component of the matrix structure opposes some resistance to the penetration of the solvent due to the
0 poor affinity towards aqueous fluids; such property being known as
10051682_l (GHMatters) P88749.AU.2 13/03/18
2018201767 13 Mar 2018
- 2 lipophilia.
2. The use of hydrophilic matrices, in which the main component of the matrix structure opposes high resistance to the progress of the solvent, in that the presence of strongly hydrophilic groups in its chains, mainly branched, remarkably increases viscosity inside the hydrated layer.
3. The use of bioerodible matrices, which are capable of being degraded by the enzymes of some biological compartment.
All the procedures listed above suffer, however, from drawbacks and imperfections.
Inert matrices, for example, generally entail non-linear, but exponential, release of the active ingredient.
Hydrophilic matrices: have a linear behaviour until a certain fraction of active ingredient has been released, then significantly deviate from linear release. Bioerodible matrices are ideal to carry out the so-called “sire-release”, but they involve the problem of finding the suitable enzyme or reactive to degradation.
Furthermore, they frequently release in situ metabolites that are not wholly toxicologically inert.
A number of formulations based on inert lipophilic matrices have been described: Drug Dev. Ind. Pharm. 13 (6), 1001-1022, (1987) discloses a process making use of varying amounts of colloidal silica as a porization element for a lipophilic inert
0 matrix in which the active ingredient is incorporated.
The same notion of canalization of an inert matrix is described in US 4,608,248 in which a small amount of a hydrophilic polymer is mixed with the substances forming an inert matrix, in a non sequential compenetration of different matrix materials. EP 375,063 discloses a technique for the preparation of multiparticulate
5 granules for the controlled-release of the active ingredient which comprises co- dissolution of polymers or suitable substances to form an inert matrix with the active ingredient and the subsequent deposition of said solution on an inert carrier which acts as the core of the device. Alternatively, the inert carrier is kneaded with the solution containing the inert polymer and the active ingredient, then the organic
0 solvent used for the dissolution is evaporated off to obtain a solid residue. The
10051682_l (GHMatters) P88749.AU.2 13/03/18
2018201767 13 Mar 2018
- 3 resulting structure is a reservoir, i.e. is not macroscopically homogeneous along all the symmetry axis of the final form. The same reservoir structure is also described in Chem. Pharm.Bull. 46 (3),531-533, (1998) which improves the application through an annealing technique of the inert polymer layer which is deposited on the surface of the pellets.
To the reservoir structure also belong the products obtained according to the technique described in WO 93/00889 which discloses a process for the preparation of pellets in hydrophilic matrix which comprises: -dissolution of the active ingredient with gastro resistant hydrophilic polymers in organic solvents; -drying of said suspension; -subsequent kneading and formulation of the pellets in a hydrophilic or lipophilic matrix without distinction of effectiveness between the two types of application. EP 0 453 001 discloses a multiparticulate with reservoir structure inserted in a hydrophilic matrix. The basic multiparticulate utilizes two coating membranes to decrease the release rate of the active ingredient, a pH15 dependent membrane with the purpose of gastric protection and a pH-independent methacrylic membrane with the purpose of slowing down the penetration of the aqueous fluid. WO 95/16451 discloses a composition only formed by a hydrophilic matrix coated with a gastro-resistant film for controlling the dissolution rate of the active ingredient. When preparing sustained-, controlled-release dosage forms of a
0 medicament topically active in the gastrointestinal tract, it is important to ensure a controlled release from the first phases following administration, i.e. when the inert matrices have the maximum release rate inside the logarithmic phase, namely the higher deviation from linear release. Said object has been attained according to the present invention, through the combination of an amphiphilic matrix inside an inert
5 matrix, the latter formulated with a lipophilic polymer in a superficial hydrophilic matrix. The compositions of the invention are characterized by the absence of a first phase in which the medicament superficially present on the matrix is quickly solubilized, and by the fact the amphiphilic layer compensate the lack of affinity of the aqueous solvent with the lipophilic compounds forming the inner inert matrix.
10051682_l (GHMatters) P88749.AU.2 13/03/18
- 4 2018201767 13 Mar 2018
DISCLOSURE OF THE INVENTION
The invention provides controlled release, delayed release, prolonged release, extended release and/or taste masking oral pharmaceutical compositions containing as active ingredient budesonide comprising:
a) a matrix consisting of lipophilic compounds with melting point lower than 90°C and optionally by amphiphilic compounds in which the active ingredient is at least partially incorporated;
b) an amphiphilic matrix;
c) an outer hydrophilic matrix in which the lipophilic matrix and the amphiphilic matrix are dispersed;
d) optionally other excipients.
A particular aspect of the invention consists of controlled release, delayed release, prolonged release, extended release and/or taste masking oral compositions containing as active ingredient budesonide comprising:
a) a matrix consisting of amphiphilic compounds and lipophilic compounds with melting point below 90°C in which the active ingredient is at least partially incorporated;
b) an outer hydrophilic matrix in which the lipophilic/amphiphilic matrix is dispersed, preferably by mixing;
c) optionally other excipients.
According to a preferred embodiment of the invention, the active ingredient budesonide is contained in the composition in an amount from 1.5 to 15% w/w, based on the total weight of the composition.
According to a preferred embodiment of the invention, budesonide is comprised in an amount from 5 to 10 mgs/dose unit, more preferably in an amount of about 6 mgs/dose unit or 9 mgs/dose unit.
A further aspect of the invention provides taste masking oral pharmaceutical compositions budesonide containing comprising:
- an inert or lipophilic matrix consisting of C6-C20 alcohols or C8-C20 fatty acids or esters of fatty acids with glycerol or sorbitol or other polyalcohols with
10051682_l (GHMatters) P88749.AU.2 13/03/18
2018201767 13 Mar 2018
- 5 carbon atom chain not higher than six:
- an amphiphilic matrix consisting of polar lipids of type 1 or II or glycols partially etherified withCl-C4 alkyl chains;
- an outer hydrophilic matrix containing the above matrices, mainly formed by saccharide, dextrin, polyalcohol or cellulose compounds or by hydrogels or their mixtures;
- optional excipients to give stability to the pharmaceutical formulation.
DETAILED DISCLOSURE OF THE INVENTION
The compositions of the invention can be prepared by a method comprising the following steps:
a) the active ingredient, represented by budesonide, is first inglobated by simple kneading or mixing in a matrix or coating consisting of compounds having amphiphilic properties, which will be further specified below. The active ingredient can be mixed with the amphiphilic compounds without the aid of solvents or with small amounts of water-alcoholic solvents.
b) the matrix obtained as specified under a) is incorporated in a low melting lipophilic excipient or mixture of excipients, if necessary while heating to soften and/or melt the excipient itself, which thereby incorporates the active ingredient
0 by simple dispersion, forming an inert matrix which can be reduced in size to obtain inert matrix granules containing the active ingredient particles.
c) the inert matrix granules are subsequently mixed together with one or more hydrophilic water-swellable excipients. The mixture is then subjected to compression or tabletting. This way, when the tablet is contacted with biological
5 fluids, a high viscosity swollen layer is formed, which coordinates the solvent molecules and acts as a barrier to penetration of the aqueous fluid itself inside the new structure. Said barrier antagonizes the starting burst effect caused by the dissolution of the medicament inglobated inside the inert matrix, which is in its turn inside the hydrophilic matrix. The amphiphilic compounds which can be
0 used according to the invention comprise polar lipids of type 1 or II (lecithin,
10051682_l (GHMatters) P88749.AU.2 13/03/18
2018201767 13 Mar 2018
- 6 phosphatidylcholine, phosphatidylethanolamine), ceramides, glycol alkyl ethers such as diethylene glycol monomethyl ether (TranscutolR). The lipophilic matrix consists of substances selected from unsaturated or hydrogenated alcohols or fatty acids, salts, esters or amides thereof, fatty acids mono-, di-or triglycerides, the polyethoxylated derivatives thereof, waxes, ceramides, cholesterol derivatives or mixtures thereof having melting point within the range of 40 to90 C, preferably from 60 to70 C. If desired, a fatty acid calcium salt may be incorporated in the lipophilic matrix which is subsequently dispersed in a hydrophilic matrix prepared with alginic acid, thus remarkably increasing the hydrophilic matrix viscosity following penetration of the solvent front until contact with the lipophilic matrix granules dispersed inside. An amphiphilic matrix with high content in active ingredient, typically from 5 to 95% w/w, in particular from 20 to 70%, or from 1.5 to 15% w/w, is first prepared by dispersing the active ingredient in a mixture of amphiphilic compounds, such as lecithin, other type II polar lipids, surfactants, or in diethylene glycol monoethyl ether; the resulting amphiphilic matrix is then mixed or kneaded, usually while hot, with lipophilic compounds suitable to form an inert matrix, such as saturated or unsaturated fatty acids, such as palmitic, stearic, myristic, lauric, laurylic, or oleic acids or mixtures thereof with other fatty acids with shorter
0 chain, or salts or alcohols or derivatives of the cited fatty acids, such as mono-, di-, or triglycerides or esters with polyethylene glycols, alone or in combination with waxes, ceramides, cholesterol derivatives or other apolar lipids in various ratios so that the melting or softening points of the lipophilic compounds mixtures is within the range of 40 to90° C, preferably from 60 to70°C.
5 Alternatively, the order of formation of the inert and amphiphilic matrices can be reversed, incorporating the inert matrix inside the amphiphilic compounds. The resulting inert lipophilic matrix is reduced into granules by an extrusion and/or granulation process, or any other known processes which retain the homogeneous dispersion and matrix structure of the starting mixture. The hydrophilic matrix consists of excipients known as hydrogels, i.e. substances
10051682_l (GHMatters) P88749.AU.2 13/03/18
- 7 2018201767 13 Mar 2018
| which when passing from the dry state to the hydrated one, undergo the socalled molecular relaxation, namely a remarkable increase in mass and weight following the coordination of a large number of water molecules by the polar groups present in the polymeric chains of the excipients themselves. Examples | |
| 5 | of hydrogels which can be used according to the invention are compounds selected from acrylic or methacrylic acid polymers or copolymers, alkylvinyl polymers, hydroxyalkyl celluloses, carboxyalkyl celluloses, polysaccharides, dextrins, pectins, starches and derivatives, natural or synthetic gums, alginic acid. In case of taste-masking formulations, the use of polyalcohols such as |
| 10 | xylitol, maltitol and mannitol as hydrophilic compounds can also be advantageous. The lipophilic matrix granules containing the active ingredient are mixed with the hydrophilic compounds cited above in a weight ratio typically ranging from 100: 0.5 to 100: 50 (lipophilic matrix: hydrophilic matrix). Part of the active ingredient can optionally be mixed with hydrophilic substances to |
| 15 | provide compositions in which the active ingredient is dispersed both in the lipophilic and the hydrophilic matrix, said compositions being preferably in the form of tablets, capsules and/or minitablets. The compression of the mixture of lipophilic and/or amphiphilic matrix, hydrogel-forming compound and, optionally, active ingredient not inglobated in the lipophilic matrix, yields a |
| 20 | macroscopically homogeneous structure in all its volume, namely a matrix containing a dispersion of the lipophilic granules in a hydrophilic matrix. A similar result can also be obtained by coating the lipophilic matrix granules with a hydrophilic polymer coating. The tablets obtainable according to the invention can optionally be subjected to known coating processes with a gastro-resistant |
| 25 | film/gastro-resistant coating, consisting of, for example, acrylic and/or methacrylic acids polymers (Eudragit (R)) or copolymers (Eudragit S/L) or cellulose derivatives, such as cellulose acetophthalate/s. According to a preferred embodiment of invention the gastro-protective coating can be represented by a mixture of acrylic and/or methacrylic acid copolymers |
| 30 | type A and/or type B (as, for example, Eudragit S100 and/or Eudragit L100). |
10051682_l (GHMatters) P88749.AU.2 13/03/18
2018201767 13 Mar 2018
- 8 According to a further embodiment of the invention, the mixture of acrylic and/or methacrylic acid copolymers type A and/or type B is preferably in a range ratio from 1:5 to 5:1.
According to another further embodiment, the gastro-protective coating also optionally comprises plasticizers, dyes, at least one water-solvent, at least one organic solvent or a mixture thereof.
The composition of the invention can further contain conventional excipients, for example bioadhesive excipients such as chitosans, polyacrylamides, natural or synthetic gums, acrylic acid polymers.
The compositions of the invention are preferably in the form of tablets, capsules or minitablets. In terms of dissolution characteristics, contact with water or aqueous fluids causes the immediate penetration of water inside the more superficial layer of the matrix which, thanks to the presence of the aqueous solvent, swells due to the distension of the polymeric chains of the hydrogels, giving rise to a high viscosity hydrated front which prevents the further penetration of the solvent itself linearly slowing down the dissolution process to a well determined point which can be located at about half the thickness, until the further penetration of water would cause the disintegration of the hydrophilic layer and therefore the release of the content which, consisting of inert matrix
0 granules, however induces the diffusion mechanism typical of these structures and therefore further slows down the dissolution profile of the active ingredient. The presence of the amphiphilic matrix inside the lipophilic matrix inert allows to prevent any unevenness of the release profile of the active ingredient. The surfactants present in the amphiphilic portion promote wettability of the porous
5 canaliculuses which cross the inert matrix preventing or reducing resistance to penetration of the solvent inside the inert matrix. To obtain taste masking tablets, the components of the hydrophilic matrix are carefully selected to minimize the active substance release time through penetration accelerated by the canalization induced by the hydrophilic compound.
0 The compositions of the present invention are preferably intended for use in the
10051682_l (GHMatters) P88749.AU.2 13/03/18
2018201767 13 Mar 2018
| 5 | treatment of subjects suffering from Inflammatory Bowel Disease and/or Irritable Bowel Syndrome. Preferably, according to the invention Inflammatory Bowel Disease is Crohn’s disease and Irritable Bowel Syndrome is Ulcerative Colitis. Further object of the invention is then a method for the treatment of a subject suffering from Inflammatory Bowel Disease and/or Irritable Bowel Syndrome comprising administering a pharmaceutical composition comprising an effective amount of budesonide, as above defined and disclosed, to a subject in need of |
| 10 | such treatment. Preferably, according to the invention Inflammatory Bowel Disease is Crohn’s disease and Irritable Bowel Syndrome is Ulcerative Colitis. According to a preferred embodiment of the invention the budesonide composition release is: - below 15% within the first hour at pH 7.2, |
| 15 | - greater than 80% within eight hours at pH 7.2. According to a further preferred embodiment of the invention the budesonide composition release is: - below 15% within the first hour at pH 7.2, |
| 20 | - below 25% within two hours at pH 7.2; - between 25% and 55% within four hours pH 7.2; - greater than 80% within eight hours at pH 7.2 According to a further preferred embodiment of the invention the budesonide composition release is: - below 15% with the first hour at pH 7.2, - between 20% and 60% within four hours at pH 7.2; |
| 25 | - greater than 80% at eight hours at pH 7.2 |
| 30 | EXPERIMENTAL PART To test the effective ability of the formulations of the invention to modify the release rate and extent of the active ingredient from the dosage form suitable for the drug administration, before any pharmacokinetic study on patients or |
10051682_l (GHMatters) P88749.AU.2 13/03/18
2018201767 13 Mar 2018
- 10 volunteers, the dissolution test is taken as monitoring and discriminating tool (according to USP type II apparatus complying with USP <711>).
Also, the bioavailability profile of the formulations of the invention is carried out, in comparison with the marked formulation Entocort® EC 3x3 mg capsules. As preferred embodiment, the bioavailability study showed a Tmax average value higher than 8 hours and a MRT average value higher than 14 hours.
According to the invention, Tmax corresponds to “time to peak concentration”,
i.e. time to reach the peak plasma concentration of a drug after oral administration (Cmax) and MRT corresponds to “mean residence time”, i.e. the average total time molecules of a given dose spend in the body. This can only be measured after instantaneous administration.
Other pharmacokinetics parameters useful according to the invention are represented by:
AUG, which corresponds to “area under the curve”, i.e. the integral of the concentration-time curve (after a single dose or in steady state). In particular, AUCo-t is the area under the curve up to the last point and AUCo.® is the area under the curve up to infinite.
Cmax, which corresponds to “peak concentration”, i.e. the peak plasma
0 concentration of a drug after oral administration.
ti/2, which corresponds to “biological half-time”, i.e. the time required for the concentration of the drag to reach half of its original value.
Xuo-36h (ng), which corresponds to “urinary excretion”, i.e. the active ingredient metabolite urinary excretion for 36 hours’ time.
5 Tiag, which corresponds to lag time, i.e. the time from administration of a drug to first quantifiable concentration.
CI, which corresponds to “confidence intervals”, i.e. a particular kind of interval estimate of a population parameter used to indicate the reliability of an estimate. CV, which corresponds to “coefficient of variation” provides a relative measure 30 of data dispersion with reference to the mean.
10051682_l (GHMatters) P88749.AU.2 13/03/18
- 11 2018201767 13 Mar 2018
| Dissolution Test Method Tablets according to the present invention undergo to dissolution test to verify the formulation capacity in modulating and controlling the rate by which the active ingredient is leaked by the device or dosage form in the environmental | |
| 5 | medium, generally a buffered solution simulating gastric or intestinal juices. The dissolution test is performed by introducing individual tablets in a glace vessel containing from 500 to 1000 ml of a buffered solution set to different pH conditions (pH 1, 6.4 and 7.2 are the pH condition generally used in this test applications), so that the whole digestive tract pH conditions, from stomach to |
| 10 | large intestine, should be reproduced. To simulate the human body conditions, the test is carried out at a temperature of 37°C ± 2°C and at predetermined time periods samples of the dissolution medium are withdrawn to detect the percentage of active ingredient dissolved over time. The tablets according to the present invention, when designed to be used to treat |
| 15 | inflammatory bowel disease, in principle have to show a good resistance, thanks to the polymeric film resistant to the low pH conditions (intended as < 5 to simulate the gastric environment) applied to cover the tablet surface, resistance which last at least for two hours; to target the large intestinal sectors, also the pH condition of 6.4 shown unsuitability to determine a drug leakage from the |
| 20 | administration device for a short exposition time and only mediums at pH 7.2 have been able to determine an active ingredient dissolution at a progressive and quite constant rate during a timeframe from 6 to 12 hours; the dissolution percentage obtained with this tablet formulation were below 15% at first hour sampling, below 25% at second hour sampling, then values were in the range |
| 25 | 25% to 55% at fourth hour and a dissolution greater than 80% was achieved at 8lh hour sampling. |
10051682_l (GHMatters) P88749.AU.2 13/03/18
- 12 2018201767 13 Mar 2018
| Bioavailabilitv study Bioavailability profile of budesonide extended release compositions (6 mg and 9 mg tablets) vs controlled release formulation (Entocort® 3x3 mg capsules) in healthy volunteers is carried out. | |
| 5 | The objectives of the study are to compare the bioavailability and PK profile of a 9 mg budesonide extended release tablet formulation of the invention (herein after referred to as Tl) versus the market reference formulation, Entocort® EC 3 x 3 mg capsules (Astra-Zeneca) (herein after referred to as R) and versus a 6 mg budesonide formulation of the invention (herein after referred to as T2). |
| 10 | The primary end-point is comparing bioavailability rate through the PK parameters of plasma budesonide Cmax and Tmax after Tl formulation versus reference formulation. The secondary end-point is comparing bioavailability extent through plasma budesonide AUCo-t after Tl formulation versus reference formulation; |
| 15 | comparing bioavailability extent through the PK parameters of plasma budesonide AUCo-t after Tl formulation versus T2 formulation; descriptive pharmacokinetics of budesonide; evaluation of main budesonide metabolite excretion in urine and safety of the test and reference formulations. Budesonide MMX™ extended release tablets 9mgs (Tl) and 6 mgs (T2) were |
| 20 | orally administered in a single dose under fasting conditions in different study periods with a wash-out interval of at least 5 days. One tablet of Tl (batch MV084) or T2 (batch TV158) was administered together with 240 mL of mineral water; the subjects were instructed to swallow the whole tablet without chewing. |
| 25 | The reference therapy was Entocort® EC 3x3 mg capsules (MP0077; AstraZeneca, Sweden), orally administered in a single dose under fasting conditions together with 240 mL of mineral water; the subjects were instructed to swallow the whole tablet without chewing. Results: |
10051682_l (GHMatters) P88749.AU.2 13/03/18
2018201767 13 Mar 2018
- 13 After administration under fasting conditions in 3 consecutive study periods of a single dose of budesonide MMXim extended release tablets 9 mg (Tl), 6 mg (T2) of the invention and Entocort EC 3x3 mg capsules (R) the PK of budesonide was found significantly different. Mean ±SD (CV%) of plasma budesonide and urine budesonide metabolite PK parameters are summarised in the tables 1-4 below for the PP population (N=12) and PP-control population (N=ll).
10051682_l (GHMatters) P88749.AU.2 13/03/18
- 14 2018201767 13 Mar 2018
Table 1
Mean +SD (CV%) budesonide PK parameters after administration of ΤΙ, T2 and
R
| MMX™ 9 mg (Tl) | MMX™ 6 mg (T2) | Entocort®EC 3x3 mg (R) | |
| PP-population (N=12) | |||
| Tnlax (h) | 13.3+5.9 (44.5) | 11.4+5.1 (44.4) | 4.8+1.4 (28.6) |
| c vmax (pg/mL) | 1348.8+958.8 (71.1) | 1158.5+532.4 (46.0) | 1555.9+588.0 (37.8) |
| AUC0.t (pgxh/mL) | 13555.9+ 7816.9 (57.7) | 10818.3+4401.6 (40.7) | 13394.6+ 5983.0 (44.7) |
| AUCo-oc (pgxh/mL) | 16431.2+ 10519.8 (64.0) | 11533.6+4738.5(41.1) | 14057.0+6378.7 (45.4) |
| (pg/mL)/dose | 149.9+106.5 (71.1) | 193.1+88.7 (46.0) | 172.9+65.3 (37.8) |
| AUC0.t (pgxh/mL) /dose | 1506.2+868.5 (57.7) | 1803.0+733.6 (40.7) | 1488.3+664.8 (44.7) |
| ti/2(h) | 8.2+3.7 (44.7) | 6.6+2.4 (36.8) | 7.7+1.8 (23.1) |
| MRT (h) | 21.4+6.8 (31.5) | 17.0+5.7 (33.7) | 11.6+2.7 (23.1) |
| PP-control population (N=l 1) | |||
| Tmax (h) | 12.8+6.0 (46.7) | 11.0+5.1 (46.4) | 4.6+1.4(29.4) |
| Cmax (pg/mL) | 1427.3+964.3 (67.6) | 1154.9+558.2 (48.3) | 1549.0+616.2 (39.8) |
| AUC0.t (pgxh/mL) | 13963.7+8063.4 (57.7) | 10331.4+4264.1 (41.3) | 13741.1+4147.5 (44.7) |
| AL'C(I.X (pgxh/mL) | 17041.8+10807.8 (63.4) | 11533.6+4738.5 (41.1) | 14462.8+6572.3 (45.4) |
| Cmax | 158.6+107.1 | 192.5+93.0 (48.3) | 172.1+68.5 |
10051682_l (GHMatters) P88749.AU.2 13/03/18
- 15 2018201767 13 Mar 2018
| (pg/mL)/dose | (67.6) | (39.8) | |
| AUC0.t (pgxh/mL) /dose | 1551.51895.9 (57.7) | 1721.9+710.7(41.3) | 1526.81683.1 (44.7) |
| ti/2(h) | 8.413.7 (44.0) | 6.612.4 (36.8) | 7.911.7(21.0) |
| MRT (h) | 21.4+7.1 (33.1) | 17.015.7 (33.7) | 11.812.7 (23.1) |
Table 2
Mean +SD (CV%) ό-β-hydroxy-budesonide cumulative excretion (Xuo.36 h) after administration of ΤΙ, T2 and R
| MMX™ 9 mg (Tl) | MMX™ 6 mg (T2) | Entocort®EC 3x3 mg (R) | |
| PP-population (N=12) | |||
| Xu0.36 h (ng) | 111061.9153992.6 | 76683.4131879.4 | 161535.4+60309.8 |
| (48.6) | (41.6) | (37.3) | |
| XU()_36 h | 12340.2+5999.2 | 12780.6+5313.2 | 17948.416701.1 |
| (ng)/dose | (48.6) | (41.6) | (37.3) |
| PP-control population (N=l 1) | |||
| Xuo-36 h (ng) | 114449.9+55273.9 | 74729.9+32673.4 | 164572.0162283.9 |
| (48.3) | (43.7) | (37.8) | |
| X 0()-36 1, | 12716.616141.5 | 12455.0+5445.6 | 18285.8+6920.4 |
| (ng)/dose | (48.3) | (43.7) | (37.8) |
10051682_l (GHMatters) P88749.AU.2 13/03/18 ο <Ν s
rΌ Γo <N 00 o <N
I co >—ι
I to _«
Ξ «
H cS
O '5 • 1—< Ό .s .s *s
| » Λ St Ο M 5 8 ό 45 ft/ IM C. < ·—· | 971.6 | 1007.8 | 1841.1 | 1618.2 | 1316.9 | 930.4 | 1031.4 | 661.9 | 2003.0 | 3902.2 | 994.1 | 1796.0 | PP population, N=12 |
| Cmax/dose (pg/mL) | 125.3 | 53.9 | 106.7 | 105.5 | 188.1 | 163.6 | 150.1 | 99.4 | 102.7 | 469.7 | 104.6 | 128.8 | |
| MRT (h) | 16.4 | 21.2 | 24.6 | 28.1 | 13.9 | 18.3 | 16.6 | 13.5 | 37.5 | 22.3 | 20.2 | 24.4 | |
| CM >*«S ~ X | 5.9 | 5.3 | 10.7 | 10.9 | 3.9 | 11.5 | 5.7 | 5.0 | 15.7 | - | 5.9 | 6.4 | |
| /—s i ε u o * < g | 9287.9 | 9713.9 | 20388.6 | 18683.2 | 12202.8 | 10125.2 | 9857.2 | 6608.2 | 30408.7 | 42027.4 | 9458.5 | 18412.6 | |
| „ J ® s A * < IM 3 | 8744.8 | 9070.4 | 16569.5 | 14563.4 | 11852.4 | 8374.0 | 9282.6 | 5957.2 | 18026.7 | 35119.3 | 8946.6 | 16164.1 | |
| * td Η Ξ U M a, | 1127.8 | 484.7 | 960.4 | 949.3 | 1692.8 | 1472.5 | 1350.7 | 894.9 | 924.5 | Cl 0 Cl Cl | 941.3 | 1159.2 | |
| X — a H | Cl | 00 | 50 | 5© r~4 | 5© | Γ· | 50 | 24 | 50 | 50 r—H | 00 | ||
| Subject | Cl | m | in | Ό | 00 | Oft | o | Cl | 107 |
(GHMatters) P88749.AU.2 13/03/18
2018201767 13 Mar 2018
(GHMatters) P88749.AU.2 13/03/18 ο
CM ro s
m
ΓSO Γo
CM o CM
C-l
H
I f—I
I rl·
Ξ « H
bO s
| ω —, » 'G' © M 5 8 ό — Q S' 00 M C. < ·—· | 682.5 | 2695.6 | 1999.9 | 1559.1 | 2292.7 | 1497.8 | 2415.5 | 552.4 | 2107.9 | 2718.3 | 1085.2 | 2029.7 | PP population, N=12 |
| Cmax/dose (pg/mL) | 83.0 | 199.6 | OS | 221.7 | 323.1 | 216.7 | 296.9 | 66.8 | 144.9 | 324.8 | 112.1 | 136.2 | |
| MRT (h) | 19.1 | 1 | 20.5 | 13.7 | 12.5 | 11.7 | 13.1 | 12.4 | 25.0 | 14.5 | 15.3 | 28.9 | |
| PM >*«S ~ -= | 6.9 | 1 | 9.3 | 5.9 | 6.4 | 3.9 | 6.9 | 3.3 | 11.7 | 5.8 | 4.7 | 7.9 | |
| /—s i ε u M * < g | 4617.4 | 1 | 13717.5 | 10383.5 | 14299 | 9398.9 | 15234.8 | 3643.1 | 15596.5 | 17261.7 | 7292.6 | 15424.7 | |
| „ J ® s A * < IM 3 | 4095.2 | 16173.8 | 11999.5 | 9354.8 | 13755.9 | 8986.8 | 14493.0 | 3314.1 | 12647.3 | 16309.7 | 6511.4 | 12178.1 | |
| * Η S u ofc a, | 498.1 | 1197.4 | 1146.8 | 1330.4 | 1938.4 | 1300.4 | 1781.2 | 400.8 | 869.6 | 1948.6 | 672.6 | 817.2 | |
| Λ — a H | Tt | SO | r- | o | os | so | 2 | r-~i | 00 | CN r—H | 24 | ||
| Subject | n | in | SO | 00 | os | o | n | 107 |
(GHMatters) P88749.AU.2 13/03/18
2018201767 13 Mar 2018
(GHMatters) P88749.AU.2 13/03/18
2018201767 22 Mar 2018
- 20 Pharmacokinetic results:
After administration under fasting conditions in 3 consecutive study periods of a single dose of Budesonide MMX™ extended release tablets 9 mg (Tl), 6 mg (T2) and Entocort® EC 3x3 mg capsules (R) the PK of budesonide was found significantly different. Mean ± SD (CV%) of plasma budesonide and urine budesonide-metabolite PK parameters are summarised in the table below for the PP population (N = 12).
Results obtained in the present study on the PP population (see table above) were confirmed by the results of the PK analysis on the PP-control population (i.e. after excluding subject randomisation Nr. 02, who showed pre-dose detectable levels) and therefore were regarded as the primary results of the study, as per protocol.
Inter-subject variability was higher for the MMX™ tablet formulation than for Entocort® EC, a finding that can be explained by the broader intestinal tract involved in the drug release from the test products (whole colon and sigmoid) as compared to the reference (terminal ileum, ascending colon) and from the absence of dose fractionation in the MMX™ formulations.
Although budesonide elimination is constant and no differences among formulations were found for ti/2 values, the different release/absorption
0 behaviour of MMX™ tablets and Entocort® EC capsules was apparent from
MRT values which were higher for the MMX™ formulations.
Analysis on Tl and R Cmax and Tmax, showed a different rate of absorption for MMX™ tablets 9 mg (Tl) with respect to Entocort® EC 3x3 mg capsules (R).
Tl had a lower budesonide concentration peak than R as confirmed by a PE% of
5 79% and 90% CI limits of 63-100%, and a significantly higher Tmax (13.3 h for
Tl vs. 4.8 h for R). Extent of absorption calculated from the AUCo-t of budesonide after administration of Tl and R was also significantly different. Tl bioavailability over the 36 h period was lower than R bioavailability (PE = 91%; 90% CI limits: 77-108%). Therefore, Tl and R were found to be non-
0 bioequivalent.
Analysis on Tmax, and dose-normalized Cmax /dose and AUCo-t /dose showed differences in rate and extent of absorption also for Tl vs. T2, As expected, Tl
10051682_l (GHMatters) P88749.AU.2 22/03/18
2018201767 22 Mar 2018
- 21 had a higher concentration peak and bioavailability than T2, although a linear relationship with dose was not observed (PE for Cmax /dose = 75%; 90% CI limits: 59 - 95%, PE for AUCo-t /dose = 80%; 90% CI limits: 67 - 94%). Therefore, T1 and T2 were found non-bioequivalent.
Tmax differences between T1 and T2 were not statistically significant (p value from t test = 0.2244). Analysis on budesonide metabolite urinary excretion (Xuo36h), showed a different excretion among formulations, with a bioequivalence not satisfied for T1 vs. R (PE = 66%; 90% CI limits: 54 - 81%) and almost achieved for T1 vs. T2 (PE= 96%, 90% CI limits: 79 - 117%).
Safety results:
The safety profile of the 3 formulations was similar. Only 3 AEs occurred during the study, 1 with T2 formulation and 2 with R formulation. Of these 3 AEs, only 1 with R formulation (i.e. headache) was judged possibly related to treatment. No meaningful effect of treatment on vital signs, ECGs or laboratory 15 parameters was observed.
Conclusions:
The formulation Budesonide MMX™ extended release tablets 9 mg was found not bioequivalent to the reference Entocort® EC 3x3 mg capsules in terms of rate and extent of bioavailability since the 90% CI for Cmax and AUCo-t did not 2 0 fall within the 80 - 125% limits required by current guidelines, and Tmax, was statistically different between MMX™ 9 mg and Entocort® EC 3x3 mg. This finding is explained by the different release behaviour of the test and reference formulations which determines different profiles of budesonide absorption.
When MMX™ 9 mg and 6 mg tablet formulations were compared to evaluate
5 dose proportionality, whereas no significant difference was found for Tmax, the analysis of dose normalised Cmax, AUCo-t indicated lack of equivalence since the 90% CI for these parameters did not fall within the 80 -125% limits required by current guidelines, but overlapped them.
The safety profile of the 3 formulations was similar and very good.
10051682_l (GHMatters) P88749.AU.2 22/03/18
- 22 2018201767 22 Mar 2018
| 5 | Pharmaco-scintigraphic and kinetic study A single dose, pharmaco-scintigraphic and kinetic study of the gastrointestinal transit and release of a 152Sm-labelled controlled release formulation of budesonide in 12 fasting male healthy volunteers is carried out. The objective of the study is to demonstrate and quantify, by pharmacoscintigraphy and PK analysis, the release and absorption of budesonide in the |
| 10 | target region. Each subject received 1 tablet of budesonide MMX™ 9 mg and an average radioactivity dose of 1.118 + 0.428 MBq as 153Sm2O3 To define the GI transit behaviour of the study formulation, images were |
| 15 | recorded at approximately 20 min intervals up to 3 h post-dose and 30 min intervals up to 10 h. Further acquisitions were taken at 12 and 24 h post-dose. The following Regions of Interest (ROIs) were defined: stomach, small intestine, terminal ileum, ileo-caecal junction and caecum, ascending, transverse, descending and sigmoid colon. Quantification of the distribution were achieved by measuring the count rates recorded from the ROIs. Budesonide plasma levels were detected between the 1st and the 12th h postadministration. On the average the appearance of drug plasma levels occurred in 6.79 ± 3.24 h (Tiag). Peak time (Tmax) averaged 14.00 ± 7.73 h, with mean |
| 20 | concentration (Cmax) of 1768.7 ± 1499.8 pg/mL. Measured average plasma AUCtin 24 h was 15607 ± 14549 pgxh/mL. The difference Tmax - Tiag accounted for 7.21 ± 5.49 h, a time period which may be representative of the release time of the active from the tablet. |
10051682_l (GHMatters) P88749.AU.2 22/03/18
2018201767 22 Mar 2018
- 23 The following table 5 summarises the main kinetic evidence:
Table 5
| N=12 | Cmax (pg/mL) | Tmax (h) | AUCt (pgxh/mL) | Tlag (h) | Tmax Tlag (h) |
| Mean | 1768.7 | 14.00 | 15607 | 6.79 | 7.21 |
| SD | 1499.8 | 7.734 | 14549 | 3.24 | 5.49 |
| CV | 84.80 | 55.24 | 93.22 | 47.66 | 76.13 |
| Min | 337.3 | 5 | 2465 | 1 | 0 |
| Max | 4756.3 | 24 | 53163 | 12 | 17 |
Combining the scintigraphic with the kinetic evidence, drug absorption during the time interval of the radioactivity location in the target ROI (i.e. the region comprised between the ascending and the descending-sigmoid colon) could be approximately calculated to amount to 95.88±4.19% of the systemically bioavailable dose.
Results:
The systemic availability of budesonide MMX™ 9 mg is mostly ascribable to the drug absorption throughout the whole colon including the sigmoid, see table 6 below:
Table 6
| AUCcolon | AUCt | AUCcoion/AUCt x 100 | |
| Mean | 15113.46 | 15606.52 | 95.88 |
| SD | 14401.79 | 14549.23 | 4.19 |
| Min | 2464.80 | 2464.80 | 84.93 |
| Max | 52376.20 | 53162.50 | 100.00 |
EXAMPLE 1
2.7 kg of budesonide,3.0 kg of lecithin (amphiphilic matrix forming material) and 3.0 kg of stearic acid (lipophilic matrix forming material) are mixing after sieving till a homogeneous mixture is obtained; then add 39.0 kg of inert, functional excipients and 9.0 kg of low viscosity hydroxypropylcellulose
10051682_l (GHMatters) P88749.AU.2 22/03/18
2018201767 22 Mar 2018
- 24 (binder) and mix for 10 minutes before adding purified water and kneading to a suitable consistence. Then pass the granulate through a rotating granulator equipped with the suitable screen and transfer the granulate to the fluid bed drier to lower the residual moisture content under 3%.
After a new sieving on the dry, the granulate is added of 9.0 kg of hydroxypropylcellulose (hydrophilic matrix forming material) and the suitable amount of functional excipients (in particular, microcrystalline cellulose, lactose and silicon dioxide) and, after 15 minutes of mixing, magnesium stearate in a suitable quantity to act 10 as lubricant is added.
After a final blending, tablets of around 300 mg of unitary weight are generated. The core is then subjected to be coated with a suspension obtained introducing into a stainless steel container 5.8 kg of Eudragit™ (methacrylate copolymers), 0.6 kg of tri ethylcitrate and 3.0 kg of dyes and talc, using alcohol as solvent.
The mean dissolution percentage (as average of six or more tablets) obtained with this tablet formulation were around 10-20% at second hour sampling, in the range 25% to 65% at fourth hour and a dissolution greater than 80% was achieved at 8th hour sampling.
10051682_l (GHMatters) P88749.AU.2 22/03/18
- 25 2018201767 22 Mar 2018
EXAMPLE 2
| Component | mg/tablet |
- Tablet
| Budesonide | 9,0 |
| Stearic Acid (lipophilic matrix forming materials) | 10,0 |
| Lecithin (amphiphilic matrix forming material) | 10,0 |
| Microcrystalline cellulose | 156,0 |
| Hydroxypropylcellulose | 60,0 |
| Lactose monohydrate | 50,0 |
| Silicon dioxide | 2,0 |
| Magnesium stearate | 3,0 |
- Coating materials
| Eudragit LI00 (acrylic and methacrylic copolymer) | 14,0 |
| Eudragit SI00 (acrylic and methacrylic copolymer) | 12,0 |
| Talc | 7,9 |
| Titanium dioxide | 4,5 |
| Triethylcitrate | 1,6 |
| Alcohol | q.s. |
The coating of industrial scale tablets of batch MV084 contained 8,0 mg of Eudragit L100 and 8,0 mg of Eudragit S100 (instead of 14,0 mg and 12,0 mg, respectively) with an individual weight of about 330 mg.
According to the present invention, coated tablets individually weighing about 340 mg are obtained.
The above described dissolution test is performed on the tablets of Example 2. The results are the following (indicated as average value):
after 2 hours at pH 1 after 1 hour at pH 6,4 after 2 hours at pH 7,2 resistent (< 5%) resistent (<5%) 15 %
10051682_l (GHMatters) P88749.AU.2 22/03/18
- 26 2018201767 22 Mar 2018
- after 4 hours at pH 7,2 37 %
- after 8 hours at pH 7,2 91 %
EXAMPLE 3
Budesonide (3.0 kg) is mixed with soybean Lecithin (5.0 kg) till a homogeneous mixture is obtained. Then carnauba wax (2.0 kg) and stearic acid (2.0 kg) sieved through a fine screen are added. After mixing, the powders are added with other functional excipients and kneaded with a binder solution obtained by dissolving medium viscosity polyvinylpyrrolidone in water. After drying in a fluid bed and milling throughout a suitable screen, hydroxypropylmethylcellulose (35.0 kg) and other excipients, including magnesium stearate as lubricant, in a suitable quantity are added and the mixture is blended till a homogeneous powder dispersion is obtained. The powder mixture is subjected to compression in a rotating tabletting machine and the tablets so obtained are coated in a pan coat with a gastroresistant composition containing Eudragit™, plasticizers, dyes and pigments.
According to the present example, coated tablets individually weighing around 105 mg are obtained.
The results of the above described dissolution test are the following (indicated as average value of at least six tablets):
after 2 hours at pH 1
- after 1 hour at pH 6,4
- after 2 hours at pH 7,2
- after 4 hours at pH 7,2 after 8 hours at pH 7,2 resistant (< 5%) resistant (<5%) 9% %
86%
EXAMPLE 4
5 50 g of diethylene glycol monoethyl ether are homogeneously distributed on 500g of microcrystalline cellulose; thenlOO g of Budesonide are added, mixing to complete homogenization. This mix is further added with 400g of Budesonide, then dispersed in a blender containing 100 g of carnauba wax and 100 g of stearic acid preheated at a temperature of 60°C. After kneading for 5 minutes, the mixture is cooled to room
0 temperature and extruded in granules of size below 1 mm. A suitable mixer is loaded with the matrix granules prepared as above and the following amounts of hydrophilic excipients: 1500 g of hydroxypropyl methylcellulose and 500 g of policarbophil™ are
10051682_l (GHMatters) P88749.AU.2 22/03/18
- 27 2018201767 22 Mar 2018 added. The components are mixed until homogeneous dispersion of the matrices, then added with 2450g of microcrystalline cellulose, 400g of lactose, 100 g of colloidal silica and 50 g of magnesium stearate. After further 5 minute mixing, the mix is tabletted to unitary weight of 250 mg/tablet.
Tablets are then subjected to coating using a suspension n containing polyacrylate and poly methacrylate copolymers in addition to other dyes, plasticizers and colouring agents in solvent (ethylic alcohol).
The results of the dissolution test performed on these coated tablets are the following (indicated as average value of at least six tablets):
after 2 hours at pH 1 after 1 hour at pH 6,4 after 2 hours at pH 7,2 after 4 hours at pH 7,2 after 8 hours at pH 7,2 resistant (< 5%) resistant (<5%) 11 %
32%
76%
In the claims which follow and in the preceding description of the invention, except where the context requires otherwise due to express language or necessary implication, the word “comprise” or variations such as “comprises” or “comprising” is used in an inclusive sense, i.e. to specify the presence of the stated features but not to preclude the 2 0 presence or addition of further features in various embodiments of the invention.
It is to be understood that, if any prior art publication is referred to herein, such reference does not constitute an admission that the publication forms a part of the common general knowledge in the art, in Australia or any other country.
10051682_l (GHMatters) P88749.AU.2 22/03/18
2018201767 22 Mar 2018
- 28 Also disclosed herein, are the following items:
1. A method for treating Inflammatory Bowel Disease (IBD) or Irritable Bowel Syndrome (IBS), comprising administering a pharmaceutical composition comprising an effective amount of Budesonide to a subject in need of such treatment, wherein the pharmaceutical composition releases:
below 15% of said amount Budesonide in a first hour at pH 7.2, and greater than 80% of said amount Budesonide in eight hours at pH 7.2.
2. The method of item 1 wherein the pharmaceutical composition releases:
below 15% of said amount Budesonide in a first hour at pH 7.2, below 25% of said amount Budesonide after a second hour at pH 7.2;
between 25% and 55% of said amount Budesonide after a fourth hour at pH 7.2; and greater than 80% after an eighth hour at pH 7.2.
3. The method of item 1 wherein the pharmaceutical composition releases:
below 15% of said amount Budesonide in a first hour at pH 7.2, between 20% and 60% of said amount Budesonide after a fourth hour at pH 7.2; and greater than 80% of said amount Budesonide after an eighth hour at pH 7.2.
4. The method of item 1 wherein the pharmaceutical composition releases less than about 5% of said amount of Budesonide after 2 hours in a pH 1 buffered solution.
0 5. The method of item 1, wherein at least some of said amount of Budesonide is released in the large intestine.
6. The method of item 1, wherein the pharmaceutical composition comprises from 1.5 to 15 % w/w of Budesonide.
7. The method of item 1, wherein the pharmaceutical composition comprises an
5 amount of Budesonide between 5 and 10 mg/dose unit.
8. The method of item 1, wherein the pharmaceutical composition comprises about 6 mgs/dose unit or about 9mgs/dose unit of Budesonide.
9. The method of item 1, wherein the Inflammatory Bowel Disease is Crohn’s disease.
10051682_l (GHMatters) P88749.AU.2 22/03/18
2018201767 22 Mar 2018
10. The method of item 1, wherein the Inflammatory Bowel Disease is Ulcerative Colitis.
11. The method of item 1, wherein the pharmaceutical composition is a multi-matrix composition comprising: (a) a lipophilic matrix; (b) an amphiphilic matrix; and (c) an outer hydrophilic matrix in which the lipophilic matrix and the amphiphilic matrix are dispersed.
12. The method of item 1, wherein Budesonide is at least partially inglobated in the amphiphilic matrix.
13. The method of item 1, wherein Budesonide is at least partially inglobated in the lipophilic matrix.
14. The method of item 1, wherein Budesonide is wholly contained in the lipophilic/amphiphilic matrix.
15. The method of item 11, wherein Budesonide is dispersed in both the outer hydrophilic matrix and the lipophilic/amphiphilic matrix.
16. The method of item 11, wherein the pharmaceutical composition further comprises (d) a gastro-resistant coating.
17. The method of item 16, wherein the gastro-protective coating is selected from acrylic and methacrylic acid polymers or copolymers and/or cellulose derivatives.
18. The method of item 17, wherein the gastro-protective coating is a mixture of acrylic 2 0 and/or methacrylic acid copolymers type A and/or type B.
19. The method of item 18, wherein the mixture of acrylic and/or methacrylic acid copolymers type A and/or type B is in a range ratio from 1:5 to 5:1.
20. The method of item 16, wherein the gastro-protective coating optionally further comprises plasticizers, dyes, at least one water solvent, at least one organic solvent or a
5 mixture thereof.
21. The method of item 1, wherein the lipophilic matrix consists of lipophilic compounds with a melting point between 40°C and 90°C.
10051682_l (GHMatters) P88749.AU.2 22/03/18
2018201767 22 Mar 2018
22. The method of item 1, wherein the lipophilic matrix consists of C6-C20 alcohols or C8-C20 fatty acids or esters of fatty acids with glycerol or sorbitol or other polyalcohols with carbon atom chain not higher than six.
23. The method of item 1, wherein the lipophilic matrix consists of a compound selected from the group consisting of unsaturated or hydrogenated alcohols or fatty acids, salts, esters or amides thereof, mono-, di- or triglycerides of fatty acids, the polyethoxylated derivatives thereof, waxes, and cholesterol derivatives.
24. The method of item 1, wherein the amphiphilic matrix comprises amphiphilic compounds selected from the group consisting of lecithin, phosphatidylcholine, phosphatidylethanolamine, ceramides, glycol alkyl ethers, esters of fatty acids with polyethylene glycols, and diethylene glycols.
25. The method of item 1, wherein the outer hydrophilic matrix is selected from the group consisting of acrylic or methacrylic acid polymers or copolymers, alkylvinyl polymers, hydroxyalkylcellulose, carboxyalkylcellulose, polysaccharides, dextrins, pectins, starches and derivatives, alginic acid, natural or synthetic gums, and polyalcohols.
26. The method of item 1, wherein the pharmaceutical composition is in the form of a tablet or capsule.
27. An oral pharmaceutical composition providing controlled release or delayed release
0 or prolonged release or extended release, or controlled release and delayed release and prolonged release and extended release thereof, said composition comprising Budesonide in a multi-matrix structure, wherein the pharmaceutical composition releases:
below 15% of said amount Budesonide in a first hour at pH 7.2, and
5 greater than 80% of said amount Budesonide in eight hours at pH 7.2.
28. The pharmaceutical composition of item 27, wherein the composition releases: below 15% of said amount Budesonide in a first hour at pH 7.2, below 25% of said amount Budesonide after a second hour at pH 7.2; between 25% and 55% of said amount Budesonide after a fourth hour at pH 7.2; and
0 greater than 80% after an eighth hour at pH 7.2.
10051682_l (GHMatters) P88749.AU.2 22/03/18
2018201767 22 Mar 2018
29. The pharmaceutical composition of item 27, wherein the composition releases: below 15% of said amount Budesonide in a first hour at pH 7.2, between 20% and 60% of said amount Budesonide after a fourth hour at pH 7.2; and greater than 80% of said amount Budesonide after an eighth hour at pH 7.2.
30. The pharmaceutical composition of item 27, wherein the composition releases less than about 5% of Budesonide after 2 hours in a pH 1 buffered solution.
31. The pharmaceutical composition of item 27, wherein the multi-matrix structure comprises: (a) a lipophilic matrix; (b) an amphiphilic matrix; and (c) an outer hydrophilic matrix in which the lipophilic matrix and the amphiphilic matrix are dispersed.
32. The pharmaceutical composition of item 27, wherein Budesonide is at least partially inglobated in the amphiphilic matrix.
33. The pharmaceutical composition of item 27, wherein Budesonide is at least partially inglobated in the lipophilic matrix.
34. The pharmaceutical composition of item 27, wherein Budesonide is wholly contained in the lipophilic/amphiphilic matrix.
35. The pharmaceutical composition of item 27, wherein Budesonide is dispersed in both the outer hydrophilic matrix and the lipophilic/amphiphilic matrix.
36. The pharmaceutical composition of item 27, further comprising (d) a gastro-
0 resistant coating.
37. The pharmaceutical composition of item 36, wherein the gastro-protective coating is selected from acrylic and methacrylic acid polymers or copolymers and/or cellulose derivatives.
38. The pharmaceutical composition of item 36, wherein the gastro-protective coating is 2 5 a mixture of acrylic and/or methacrylic acid copolymers type A and/or type B.
39. The pharmaceutical composition of item 37, wherein the mixture of acrylic and/or methacrylic acid copolymers type A and/or type B is in a range ratio from 1:5 to 5:1.
10051682_l (GHMatters) P88749.AU.2 22/03/18
2018201767 22 Mar 2018
40. The pharmaceutical composition of item 36 wherein the gastro-protective coating optionally further comprises plasticizers, dyes, at least one water solvent, at least one organic solvents or a mixture thereof.
41. The pharmaceutical composition of item 26, wherein the lipophilic matrix consists of lipophilic compounds with a melting point between 40°C and 90°C.
42. The pharmaceutical composition of item 26, wherein the lipophilic matrix consists of C6-C20 alcohols or C8-C20 fatty acids or esters of fatty acids with glycerol or sorbitol or other polyalcohols with carbon atom chain not higher than six.
43. The pharmaceutical composition of item 26, wherein the lipophilic matrix consists of a compound selected from the group consisting of unsaturated or hydrogenated alcohols or fatty acids, salts, esters or amides thereof, mono-, di-or triglycerides of fatty acids, the polyethoxylated derivatives thereof, waxes, and cholesterol derivatives.
44. The pharmaceutical composition of item 26, wherein the amphiphilic matrix comprises amphiphilic compounds selected from the group consisting of polar lipids of type I or II (lecithin, phosphatidylcholine, phosphatidylethanolamine), ceramides, glycol alkyl ethers, esters of fatty acids with polyethylene glycols, and diethylene glycols.
45. The pharmaceutical composition of item 26, wherein the outer hydrophilic matrix is selected from the group consisting of acrylic or methacrylic acid polymers or
0 copolymers, alkylvinyl polymers, hydroxyalkylcellulose, carboxyalkylcellulose, polysaccharides, dextrins, pectins, starches and derivatives, alginic acid, natural or synthetic gums, and polyalcohols.
46. The pharmaceutical composition of item 26, in the form of a tablet or capsule.
47. The pharmaceutical composition of item 26, wherein Budesonide is present in an
5 amount 1.5 to 15% w/w.
48. The pharmaceutical composition of item 26, wherein the Budesonide is present in an amount ranging from 5 to 10 mgs/unit dose.
49. The pharmaceutical composition of item 48, wherein the Budesonide is present in an amount of about 6 mgs/unit dose or of about 9 mgs/unit dose.
10051682_l (GHMatters) P88749.AU.2 22/03/18
2018201767 22 Mar 2018
50. An oral pharmaceutical composition providing controlled release or delayed release, or controlled release and delayed release thereof, the composition comprising Budesonide in a multi-matrix structure, wherein the composition has a Tmax of between about 5 and 24 hours post administration as determined by Budesonide plasma concentration.
51. The composition of item 50, wherein the composition has a mean Tmax greater than about 10 hours.
52. The composition of item 50, wherein the composition has a mean Tmax of about 14.00+/-7.73 hours.
53. The composition of item 50, wherein the composition has a mean Tmax of about
13.3+/- 5.9 hours.
54. The composition of item 50, wherein the composition has a mean Tmax of about
11.4 +/- 5.1 hours.
55. The composition of item 50, wherein the composition has a tiag of between about 1 and 12 hours, wherein tiag is the time between administration of the composition and the time that Budesonide is first detected in plasma.
56. The composition of item 50, wherein the composition has a mean tiag of about 6.79+/-3.24 hours.
57. The composition of item 50, wherein the composition has an MRT (Mean
0 Residence Time) of between about 11.7 hours and 37.5 hours following administration.
58. The composition of item 50, wherein the composition has a mean MRT of about 21.4+/-6.8 hours following administration.
59. The composition of item 50, wherein the composition has a mean MRT of about 17.0+/-5.7 hours following administration.
5 60. The composition of item 50, wherein upon administration, the systemic availability of Budesonide in the colon (AUCcolon) between about 84.93 and 100% of the total availability (AUCt) wherein AUC is the area under the plasma concentration verses time curve.
10051682_l (GHMatters) P88749.AU.2 22/03/18
2018201767 22 Mar 2018
61. The composition of item 50, wherein upon administration, the mean systemic availability of Budesonide in the colon is about 95.88 +/- 4.19% of the total availability.
62. The composition of item 50, wherein the composition has an AUCinf between about 3643.1 and 42027.4 pgxh/mL.
63. The composition of item 50, wherein the composition has a mean AUCinf of about
16431.2+/-10519.8 pgxh/mL.
64. The composition of item 50, wherein the composition has a mean AUCinf of about 11533.6+/-4738.5 pgxh/mL.
65. The composition of item 50, wherein the multi-matrix structure comprises: (a) a lipophilic matrix; (b) an amphiphilic matrix; and (c) an outer hydrophilic matrix in which the lipophilic matrix and the amphiphilic matrix are dispersed.
66. The composition of item 65, wherein Budesonide is at least partially inglobated in the amphiphilic matrix.
67. The composition of item 65, wherein Budesonide is at least partially inglobated in 15 the lipophilic matrix.
68. The composition of item 65, wherein Budesonide is wholly contained in the lipophilic/amphiphilic matrix.
69. The composition of item 65, wherein Budesonide is dispersed in both the outer hydrophilic matrix and the lipophilic/amphiphilic matrix.
0 70. The composition of item 65, further comprising (d) a gastro-resistant coating.
71. The composition of item 70, wherein the gastro-protective coating is selected from acrylic and methacrylic acid polymers or copolymers and/or cellulose derivatives.
72. The composition of item 70, wherein the gastro-protective coating is a mixture of methacrylic acid copolymers type A and/or type B.
5 73. The composition of item 72, wherein the mixture of methacrylic acid copolymers type A and/or type B is in a range ratio from 1:5 to 5:1.
10051682_l (GHMatters) P88749.AU.2 22/03/18
2018201767 22 Mar 2018
74. The composition of item 70, wherein the gastro-protective coating optionally further comprises plasticizers, dyes, at least one water solvent, at least one organic solvents or a mixture thereof.
75. The composition of item 65, wherein the lipophilic matrix consists of lipophilic compounds with a melting point between 40°C and 90°C.
76. The composition of item 65, wherein the lipophilic matrix consists of C6-C20 alcohols or C8-C20 fatty acids or esters of fatty acids with glycerol or sorbitol or other polyalcohols with carbon atom chain not higher than six.
77. The composition of item 65, wherein the lipophilic matrix consists of a compound selected from the group consisting of unsaturated or hydrogenated alcohols or fatty acids, salts, esters or amides thereof, mono-, di-or triglycerides of fatty acids, the polyethoxylated derivatives thereof, waxes, and cholesterol derivatives.
78. The composition of item 65, wherein the amphiphilic matrix comprises amphiphilic compounds selected from the group consisting of lecithin, phosphatidylcholine, phosphatidylethanolamine, ceramides, glycol alkyl ethers, esters of fatty acids with polyethylene glycols, and diethylene glycols.
79. The composition of item 65, wherein the outer hydrophilic matrix is selected from the group consisting of acrylic or methacrylic acid polymers or copolymers, alkylvinyl polymers, hydroxyalkylcellulose, carboxyalkylcellulose, polysaccharides, dextrins,
0 pectins, starches and derivatives, alginic acid, natural or synthetic gums, and polyalcohols.
80. The composition of item 50, in the form of a tablet or capsule.
81. The composition of item 50, wherein the Budesonide is present in an amount ranging from 5 to 10 mgs/unit dose
5 82. The composition of item 50, wherein the Budesonide is present in an amount of about 6 mgs/unit dose or of about 9 mgs/unit dose.
83. The composition of item 50, wherein the composition is for the treatment of Inflammatory Bowel Disease (IBD) or Irritable Bowel Syndrome (IBS).
10051682_l (GHMatters) P88749.AU.2 22/03/18
2018201767 22 Mar 2018
84. The composition of item 83, wherein the IBD is colonic Crohn’s disease or Ulcerative Colitis.
85. A method for treating Inflammatory Bowel Disease (IBD) or Irritable Bowel Syndrome (IBS), comprising administering to a subject in need of such treatment a pharmaceutical composition comprising an effective amount of budesonide as an active ingredient incorporated into a multi-matrix comprising: (a) a lipophilic matrix; (b) an amphiphilic matrix; and (c) an outer hydrophilic matrix in which the lipophilic matrix and the amphiphilic matrix are dispersed, wherein:
- less than 15% of the budesonide is released from said pharmaceutical composition within a first hour at pH 7.2; and
- greater than 80% of the budesonide is released from said pharmaceutical composition within eight hours at pH 7.2.
86. The method of item 85 wherein:
- less than 15% of the budesonide is released from said pharmaceutical composition within a first hour at pH 7.2;
- less than 25% of the budesonide is released from said pharmaceutical composition within a second hour at pH 7.2;
- between 25% and 55% of the budesonide is released from said pharmaceutical composition within fourth hours at pH 7.2;
0 - greater than 80% of the budesonide is released from said pharmaceutical composition within eight hours at pH 7.2.
87. The method of item 85 wherein:
- less than 15% of the budesonide is released from said pharmaceutical composition within a first hour at pH 7.2;
5 - between 20% and 60% of the budesonide is released from said pharmaceutical composition within fourth hours at pH 7.2;
- greater than 80% of the budesonide is released from said pharmaceutical composition within eight hours at pH 7.2.
88. The method of item 85 wherein less than 5% of the budesonide is released from said
0 pharmaceutical composition within 2 hours in a pH 1 buffered solution.
10051682_l (GHMatters) P88749.AU.2 22/03/18
2018201767 22 Mar 2018
89. The method of item 85 wherein less than 5% of the budesonide is released from said pharmaceutical composition within 1 hour in a pH 6.4 buffered solution.
90. The method of item 85, wherein at least some budesonide is released in the large intestine.
91. The method of item 85, wherein the pharmaceutical composition comprises from
1.5 to 15 % w/w of budesonide.
92. The method of item 85, wherein the pharmaceutical composition comprises an amount of budesonide between 5 and 10 mg/dose unit.
93. The method of item 85, wherein the pharmaceutical composition comprises about 6 10 mgs/dose unit or about 9mgs/dose unit of Budesonide.
94. The method of item 85, wherein the Inflammatory Bowel Disease is Crohn’s disease.
95. The method of item 85, wherein the Inflammatory Bowel Disease is Ulcerative Colitis.
96. The method of item 85, wherein budesonide is at least partially inglobated in the amphiphilic matrix.
97. The method of item 85, wherein budesonide is at least partially inglobated in the lipophilic matrix.
98. The method of item 85, wherein budesonide is wholly contained in the
0 lipophilic/amphiphilic matrix.
99. The method of item 85, wherein budesonide is dispersed in both the outer hydrophilic matrix and the lipophilic/amphiphilic matrix.
100. The method of item 85, wherein the pharmaceutical composition further comprises (d) a gastro-resistant coating.
5 101. The method of item 100, wherein the gastro-protective coating is selected from acrylic and methacrylic acid polymers or copolymers and/or cellulose derivatives.
102. The method of item 100, wherein the gastro-protective coating is a mixture of acrylic and/or methacrylic acid copolymers type A and/or type B.
10051682_l (GHMatters) P88749.AU.2 22/03/18
2018201767 22 Mar 2018
103. The method of item 100, wherein the mixture of acrylic and/or methacrylic acid copolymers type A and/or type B is in a range ratio from 1:5 to 5:1.
104. The method of item 100, wherein the gastro-protective coating optionally further comprises plasticizers, dyes, at least one water solvent, at least one organic solvent or a mixture thereof.
105. The method of item 85, wherein the lipophilic matrix consists of lipophilic compounds with a melting point between 40°C and 90°C.
106. The method of item 85, wherein the lipophilic matrix consists of C6-C20 alcohols or C8-C20 fatty acids or esters of fatty acids with glycerol or sorbitol or other polyalcohols with carbon atom chain not higher than six.
107. The method of item 85, wherein the lipophilic matrix consists of a compound selected from the group consisting of unsaturated or hydrogenated alcohols or fatty acids, salts, esters or amides thereof, mono-, di- or triglycerides of fatty acids, the polyethoxylated derivatives thereof, waxes, and cholesterol derivatives.
108. The method of item 85, wherein the amphiphilic matrix comprises amphiphilic compounds selected from the group consisting of polar lipids of type I or II (lecithin, phosphatidylcholine, phosphatidylethanolamine), ceramides, glycol alkyl ethers, esters of fatty acids with polyethylene glycols, and diethylene glycols.
109. The method of item 85, wherein the outer hydrophilic matrix is selected from
0 the group consisting of acrylic or methacrylic acid polymers or copolymers, alkylvinyl polymers, hydroxyalkylcellulose, carboxyalkylcellulose, polysaccharides, dextrins, pectins, starches and derivatives, alginic acid, natural or synthetic gums, and polyalcohols.
110. The method of item 85, wherein the pharmaceutical composition is in the form
5 of a tablet or capsule.
111. An oral pharmaceutical composition providing controlled release or delayed release or prolonged release or extended release, said composition comprising budesonide as an active ingredient incorporated into a multi-matrix comprising: (a) a lipophilic matrix; (b) an amphiphilic matrix; and (c) an outer hydrophilic matrix in
0 which the lipophilic matrix and the amphiphilic matrix are dispersed, wherein:
10051682_l (GHMatters) P88749.AU.2 22/03/18
2018201767 22 Mar 2018
- 39 less than 15% of the budesonide is released from said pharmaceutical composition within a first hour at pH 7.2, and greater than 80% of the budesonide is released from said pharmaceutical composition within eight hours at pH 7.2.
112. The pharmaceutical composition of item 111, wherein:
less than 15% of the budesonide is released from said pharmaceutical composition within a first hour at pH 7.2, less than 25% of the budesonide is released from said pharmaceutical composition within a second hour at pH 7.2;
between 25% and 55% of the budesonide is released from said pharmaceutical composition within four hours at pH 7.2; and greater than 80% of the budesonide is released from said pharmaceutical composition within eight hours at pH 7.2.
113. The pharmaceutical composition of item 111, wherein:
less than 15% of the budesonide is released from said pharmaceutical composition within a first hour at pH 7.2;
between 20% and 60% of the budesonide is released from said pharmaceutical composition within four hours at pH 7.2; and greater than 80% of the budesonide is released from said pharmaceutical composition 2 0 within eight hours at pH 7.2.
114. The pharmaceutical composition of item 111, wherein less than 5% of the budesonide is released from said pharmaceutical composition within 2 hours in a pH 1 buffered solution.
115. The pharmaceutical composition of item 111, wherein budesonide is at least
5 partially inglobated in the amphiphilic matrix.
116. The pharmaceutical composition of item 111, wherein budesonide is at least partially inglobated in the lipophilic matrix.
117. The pharmaceutical composition of item 111, wherein budesonide is wholly contained in the lipophilic/amphiphilic matrix.
10051682_l (GHMatters) P88749.AU.2 22/03/18
2018201767 22 Mar 2018
118. The pharmaceutical composition of item 111, wherein budesonide is dispersed in both the outer hydrophilic matrix and the lipophilic/amphiphilic matrix.
119. The pharmaceutical composition of item 111, further comprising (d) a gastroresistant coating.
120. The pharmaceutical composition of item 119, wherein the gastro-protective coating is selected from acrylic and methacrylic acid polymers or copolymers and/or cellulose derivatives.
121. The pharmaceutical composition of item 119, wherein the gastro-protective coating is a mixture of acrylic and/or methacrylic acid copolymers type A and/or type
B.
122. The pharmaceutical composition of item 119, wherein the mixture of acrylic and/or methacrylic acid copolymers type A and/or type B is in a range ratio from 1:5 to 5:1.
123. The pharmaceutical composition of item 119 wherein the gastro-protective coating optionally further comprises plasticizers, dyes, at least one water solvent, at least one organic solvents or a mixture thereof.
124. The pharmaceutical composition of item 111, wherein the lipophilic matrix consists of lipophilic compounds with a melting point between 40°C and 90°C.
125. The pharmaceutical composition of item 111, wherein the lipophilic matrix
0 consists of C6-C20 alcohols or C8-C20 fatty acids or esters of fatty acids with glycerol or sorbitol or other polyalcohols with carbon atom chain not higher than six.
126. The pharmaceutical composition of item 111, wherein the lipophilic matrix consists of a compound selected from the group consisting of unsaturated or hydrogenated alcohols or fatty acids, salts, esters or amides thereof, mono-, di-or
5 triglycerides of fatty acids, the polyethoxylated derivatives thereof, waxes, and cholesterol derivatives.
127. The pharmaceutical composition of item 111, wherein the amphiphilic matrix comprises amphiphilic compounds selected from the group consisting of polar lipids of type I or II (lecithin, phosphatidylcholine, phosphatidylethanolamine), ceramides,
10051682_l (GHMatters) P88749.AU.2 22/03/18
2018201767 22 Mar 2018
- 41 glycol alkyl ethers, esters of fatty acids with polyethylene glycols, and diethylene glycols.
128. The pharmaceutical composition of item 111, wherein the outer hydrophilic matrix is selected from the group consisting of acrylic or methacrylic acid polymers or copolymers, alkylvinyl polymers, hydroxyalkylcellulose, carboxyalkylcellulose, polysaccharides, dextrins, pectins, starches and derivatives, alginic acid, natural or synthetic gums, and polyalcohols.
129. The pharmaceutical composition of item 111, in the form of a tablet or capsule.
130. The pharmaceutical composition of item 111, wherein budesonide is present in an amount 1.5 to 15% w/w.
131. The pharmaceutical composition of item 111, wherein the budesonide is present in an amount ranging from 5 to 10 mgs/unit dose.
132. The pharmaceutical composition of item 111, wherein the budesonide is present in an amount of about 6 mgs/unit dose or of about 9 mgs/unit dose.
133. A method for treating Inflammatory Bowel Disease (IBD) or Irritable Bowel
Syndrome (IBS), comprising administering to a subject in need of such treatment a pharmaceutical composition comprising budesonide as an active ingredient incorporated into a matrix granule comprising: (a) a lipophilic matrix; and (b) an amphiphilic matrix; wherein said granule is coated with a hydrophilic polymer.
0 134. The method of item 133, wherein said granule is less than 1 mm in diameter.
135. An oral pharmaceutical composition providing controlled release or delayed release or prolonged release or extended release, said composition comprising budesonide as an active ingredient incorporated into a matrix granule comprising: (a) a lipophilic matrix; and (b) an amphiphilic matrix; wherein said granule is coated with a
5 hydrophilic polymer.
136. The oral pharmaceutical composition of hem 135, wherein said granule is less than 1 mm in diameter.
10051682_l (GHMatters) P88749.AU.2 22/03/18
Claims (10)
1. An oral pharmaceutical composition administered to a human, wherein said oral pharmaceutical composition is in the form of a tablet, said tablet comprising:
2 5 budesonide in said human of about 1348.8+958.8 pg/mL following said administration of said oral pharmaceutical composition to said human.
25. The oral pharmaceutical composition administered to a human according to claim
19, wherein said oral pharmaceutical composition provides a mean Tmax of said
2 5 iii) 10 mg lecithin; and iv) 60 mg hydroxypropyl cellulose; and (b) a tablet coating comprising a gastro-resistant film comprising 16 mg acrylic acid and methacrylic copolymer;
wherein said oral pharmaceutical composition releases: below 15% of said budesonide
2 0 19. An oral pharmaceutical composition administered to a human, wherein said oral pharmaceutical composition is in the form of a tablet, said tablet comprising:
(a) a tablet core comprising:
i) 9 mg of budesonide;
ii) 10 mg stearic acid;
2 5 10, wherein said oral pharmaceutical composition provides a mean AUCoj of said budesonide in said human of about 35119.3 (pg)(hr)/mL to about 5957.2 (pg)(hr)/mL in 36 hours following said administration of said oral pharmaceutical composition to said human.
2 0 10, wherein said oral pharmaceutical composition provides a mean AU Co infinity of said budesonide in said human of about 42027.4 (pg)(hr)/mL to about 6608.2 (pg)(hr)/mL following said administration of said oral pharmaceutical composition to said human.
14. The oral pharmaceutical composition administered to a human according to claim
2. The oral pharmaceutical composition administered to a human according to claim 1, wherein said oral pharmaceutical composition provides a Cmax of said budesonide in said human of from about 485 pg/mL to about 4227 pg/mL following said administration of said oral pharmaceutical composition to said human.
3 0 budesonide in said human of about 13.3+5.9 hours following said administration of said oral pharmaceutical composition to said human.
11349500_l (GHMatters) P88749.AU.2 17/05/19
2018201767 17 May 2019
26. The oral pharmaceutical composition administered to a human according to claim
19, wherein said oral pharmaceutical composition provides a mean AU Co infinity of said budesonide in said human of about 16431.2±10519.8 (pg) (hr)/mL following said
3 0 within the first hour at pH 7.2; between 20% and 60% of said amount of budesonide within four hours at pH 7.2; and greater than 80% of said amount of budesonide within eight hours at pH 7.2.
11349500_l (GHMatters) P88749.AU.2 17/05/19
2018201767 17 May 2019
20. The oral pharmaceutical composition administered to a human according to claim
19, wherein said oral pharmaceutical composition provides a Cmax of said budesonide in said human of from about 485 pg/mL to about 4227 pg/mL following said
3 0 15. The oral pharmaceutical composition administered to a human according to claim
10, wherein said oral pharmaceutical composition provides a mean Cmax of said
11349500_l (GHMatters) P88749.AU.2 17/05/19
2018201767 17 May 2019 budesonide in said human of about 1348.8±958.8 pg/mL following said administration of said oral pharmaceutical composition to said human.
16. The oral pharmaceutical composition administered to a human according to claim
3 0 ii) 10 mg stearic acid;
iii) 10 mg lecithin; and iv) 60 mg hydroxypropyl cellulose; and
11349500_l (GHMatters) P88749.AU.2 17/05/19
2018201767 17 May 2019 (b) a tablet coating comprising a gastro-resistant film comprising 16 mg of acrylic acid and methacrylic copolymer;
wherein said oral pharmaceutical composition releases: below 15% of said budesonide within the first hour at pH 7.2; below 25% of said amount of budesonide within two
3. The oral pharmaceutical composition administered to a human according to claim 1, wherein said oral pharmaceutical composition provides a Tmax of said budesonide in said human of from about 6 hours to about 24 hours following said administration of said oral pharmaceutical composition to said human.
4. The oral pharmaceutical composition administered to a human according to claim 1, wherein said oral pharmaceutical composition provides a mean ATJCojnfinity of said budesonide in said human of about 42027.4 (pg)(hr)/mL to about 6608.2 (pg)(hr)/mL following said administration of said oral pharmaceutical composition to said human.
5 administration of said oral pharmaceutical composition to said human.
27. The oral pharmaceutical composition administered to a human according to claim
19, wherein said oral pharmaceutical composition provides a mean AUCoj of said budesonide in said human of about 13555.9±7816.9 (pg)(hr)/mL in 36 hours following
5 administration of said oral pharmaceutical composition to said human.
21. The oral pharmaceutical composition administered to a human according to claim
19, wherein said oral pharmaceutical composition provides a Tmax of said budesonide in said human of from about 6 hours to about 24 hours following said administration of 10 said oral pharmaceutical composition to said human.
22. The oral pharmaceutical composition administered to a human according to claim
19, wherein said oral pharmaceutical composition provides a mean ATJCojnfinity of said budesonide in said human of about 42027.4 (pg)(hr)/mL to about 6608.2 (pg)(hr)/mL 15 following said administration of said oral pharmaceutical composition to said human.
23. The oral pharmaceutical composition administered to a human according to claim
19, wherein said oral pharmaceutical composition provides a mean AUCo rof said budesonide in said human of about 35119.3 (pg)(hr)/mL to about 5957.2 (pg)(hr)/mL in 2 0 36 hours following said administration of said oral pharmaceutical composition to said human.
24. The oral pharmaceutical composition administered to a human according to claim
19, wherein said oral pharmaceutical composition provides a mean Cmax of said
5 10, wherein said oral pharmaceutical composition provides a mean Tmax of said budesonide in said human of about 13.3±5.9 hours following said administration of said oral pharmaceutical composition to said human.
10 17. The oral pharmaceutical composition administered to a human according to claim
10, wherein said oral pharmaceutical composition provides a mean AUCojnfinity of said budesonide in said human of about 16431.2±10519.8 (pg) (hr)/mL following said administration of said oral pharmaceutical composition to said human.
15 18. The oral pharmaceutical composition administered to a human according to claim
10, wherein said oral pharmaceutical composition provides a mean AUCoj of said budesonide in said human of about 13555.9±7816.9 (pg)(hr)/mL in 36 hours following said administration of said oral pharmaceutical composition to said human.
5 hours at pH 7.2; between 25% and 55% of said amount of budesonide within four hours at pH 7.2; and greater than 80% of said amount of budesonide within eight hours at pH 7.2.
11. The oral pharmaceutical composition administered to a human according to claim
10 10, wherein said oral pharmaceutical composition provides a Cmax of said budesonide in said human of from about 485 pg/mL to about 4227 pg/mL following said administration of said oral pharmaceutical composition to said human.
12. The oral pharmaceutical composition administered to a human according to claim
15 10, wherein said oral pharmaceutical composition provides a Tmax of said budesonide in said human of from about 6 hours to about 24 hours following said administration of said oral pharmaceutical composition to said human.
13. The oral pharmaceutical composition administered to a human according to claim
5. The oral pharmaceutical composition administered to a human according to claim 1, wherein said oral pharmaceutical composition provides a mean AUCoj of said
11349500_l (GHMatters) P88749.AU.2 17/05/19
2018201767 17 May 2019 budesonide in said human of about 35119.3 (pg)(hr)/mL to about 5957.2 (pg)(hr)/mL in 36 hours following said administration of said oral pharmaceutical composition to said human.
5
5 (a) a tablet core comprising:
i) 9 mg of budesonide;
ii) 10 mg stearic acid and/or magnesium stearate;
iii) 10 mg lecithin; and iv) 60 mg hydroxypropyl cellulose; and
10 (b) a tablet coating comprising a gastro-resistant film comprising 16 mg of acrylic acid and methacrylic copolymer;
wherein said oral pharmaceutical composition releases: below 15% of said budesonide within the first hour at pH 7.2; and greater than 80% of said amount of budesonide within eight hours at pH 7.2.
6. The oral pharmaceutical composition administered to a human according to claim 1, wherein said oral pharmaceutical composition provides a mean Cmax of said budesonide in said human of about 1348.8±958.8 pg/mL following said administration of said oral pharmaceutical composition to said human.
10
7. The oral pharmaceutical composition administered to a human according to claim 1, wherein said oral pharmaceutical composition provides a mean Tmax of said budesonide in said human of about 13.3±5.9 hours following said administration of said oral pharmaceutical composition to said human.
8. The oral pharmaceutical composition administered to a human according to claim 1, wherein said oral pharmaceutical composition provides a mean ATJCojnfinity of said budesonide in said human of about 16431.2±10519.8 (pg) (hr)/mL following said administration of said oral pharmaceutical composition to said human.
9. The oral pharmaceutical composition administered to a human according to claim 1, wherein said oral pharmaceutical composition provides a mean AUCoj of said budesonide in said human of about 13555.9±7816.9 (pg)(hr)/mL in 36 hours following said administration of said oral pharmaceutical composition to said human.
10. An oral pharmaceutical composition administered to a human, wherein said oral pharmaceutical composition is in the form of a tablet, said tablet comprising:
(a) a tablet core comprising:
i) 9 mg of budesonide;
10 said administration of said oral pharmaceutical composition to said human.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2018201767A AU2018201767B2 (en) | 2011-11-09 | 2018-03-13 | Controlled release and taste masking oral pharmaceutical composition |
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2011248587A AU2011248587A1 (en) | 2011-11-09 | 2011-11-09 | Controlled release and taste masking oral pharmaceutical composition |
| AU2011248587 | 2011-11-09 | ||
| AU2016203566A AU2016203566B2 (en) | 2011-11-09 | 2016-05-30 | Controlled release and taste masking oral pharmaceutical composition |
| AU2018201767A AU2018201767B2 (en) | 2011-11-09 | 2018-03-13 | Controlled release and taste masking oral pharmaceutical composition |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2016203566A Division AU2016203566B2 (en) | 2011-11-09 | 2016-05-30 | Controlled release and taste masking oral pharmaceutical composition |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2018201767A1 AU2018201767A1 (en) | 2018-04-05 |
| AU2018201767B2 true AU2018201767B2 (en) | 2019-06-06 |
Family
ID=48431830
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2011248587A Abandoned AU2011248587A1 (en) | 2011-11-09 | 2011-11-09 | Controlled release and taste masking oral pharmaceutical composition |
| AU2016203566A Ceased AU2016203566B2 (en) | 2011-11-09 | 2016-05-30 | Controlled release and taste masking oral pharmaceutical composition |
| AU2018201767A Active AU2018201767B2 (en) | 2011-11-09 | 2018-03-13 | Controlled release and taste masking oral pharmaceutical composition |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2011248587A Abandoned AU2011248587A1 (en) | 2011-11-09 | 2011-11-09 | Controlled release and taste masking oral pharmaceutical composition |
| AU2016203566A Ceased AU2016203566B2 (en) | 2011-11-09 | 2016-05-30 | Controlled release and taste masking oral pharmaceutical composition |
Country Status (1)
| Country | Link |
|---|---|
| AU (3) | AU2011248587A1 (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2000076478A1 (en) * | 1999-06-14 | 2000-12-21 | Cosmo S.P.A. | Controlled release and taste masking oral pharmaceutical compositions |
| WO2010144865A2 (en) * | 2009-06-12 | 2010-12-16 | Meritage Pharma, Inc. | Methods for treating gastrointestinal disorders |
| WO2012052918A1 (en) * | 2010-10-19 | 2012-04-26 | Cosmo Technologies Ltd. | Use of mexiprostil in the treatment of inflammatory bowel disease and/or of irritable bowel syndrome |
-
2011
- 2011-11-09 AU AU2011248587A patent/AU2011248587A1/en not_active Abandoned
-
2016
- 2016-05-30 AU AU2016203566A patent/AU2016203566B2/en not_active Ceased
-
2018
- 2018-03-13 AU AU2018201767A patent/AU2018201767B2/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2000076478A1 (en) * | 1999-06-14 | 2000-12-21 | Cosmo S.P.A. | Controlled release and taste masking oral pharmaceutical compositions |
| WO2010144865A2 (en) * | 2009-06-12 | 2010-12-16 | Meritage Pharma, Inc. | Methods for treating gastrointestinal disorders |
| WO2012052918A1 (en) * | 2010-10-19 | 2012-04-26 | Cosmo Technologies Ltd. | Use of mexiprostil in the treatment of inflammatory bowel disease and/or of irritable bowel syndrome |
Also Published As
| Publication number | Publication date |
|---|---|
| AU2016203566B2 (en) | 2017-12-14 |
| AU2016203566A1 (en) | 2016-06-16 |
| AU2018201767A1 (en) | 2018-04-05 |
| AU2011248587A1 (en) | 2013-05-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US8895064B2 (en) | Controlled release and taste masking oral pharmaceutical composition | |
| US8029823B2 (en) | Controlled release and taste masking oral pharmaceutical composition | |
| AU2018201767B2 (en) | Controlled release and taste masking oral pharmaceutical composition | |
| US10660858B2 (en) | Controlled release and taste masking oral pharmaceutical composition | |
| BRPI1105676A2 (en) | Method for treating inflammatory bowel disease (ibd) or irritable bowel syndrome (ibs), and, oral pharmaceutical composition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGA | Letters patent sealed or granted (standard patent) |